Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597727 | 0.89 | AKR1B1 (0.46) | KDM4AIDO1GRM2KCNA5EPHX2 | |
| SCHEMBL31156791 | 0.86 | NQO2 (0.49) | IDO1BRD4 | |
| SCHEMBL18041423 | 0.86 | NQO2 (0.49) | IDO1BRD4 | |
| SCHEMBL23762070 | 0.86 | KCNA5 (0.46) | KDM4AIDO1GRM2KCNA5EPHX2 | |
| SCHEMBL29350331 | 0.86 | KDM4A (0.45) | KDM4AIDO1KCNA5EPHX2NR1H4 | |
| SCHEMBL12330489 | 0.86 | KDM4A (0.45) | KDM4AIDO1KCNA5EPHX2NR1H4 | |
| SCHEMBL654820 | 0.86 | KDM4A (0.45) | KDM4AIDO1KCNA5EPHX2NR1H4 | |
| SCHEMBL13104124 | 0.84 | KDM4A (0.44) | KDM4AIDO1JAK2JAK1KCNA5 | |
| SCHEMBL24885830 | 0.84 | NQO2 (0.49) | KDM4AJAK2JAK1KCNA5CTSS | |
| SCHEMBL12206607 | 0.84 | KDM4A (0.41) | KDM4AIDO1JAK2JAK1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170834-B1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | ABBVIE INC (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8110572-B2 | Inhibitors of protein kinases | ABBOTT LABORATORIES (US) | 2012-02-07 | — | — | US | disclosed |
| US-20120015961-A1 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-2170834-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | Abbott Laboratories (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090054430-A1 | Inhibitors of Protein Kinases | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2009012312-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015961-A1 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, BACE2, APP | KDM4A 2399/4885IDO1 2992/4885JAK2 4264/4885 |
| US-20090054430-A1 | Inhibitors of Protein Kinases | AURKC, AURKB, PLK1 | KDM4A 2929/4885IDO1 3805/4885JAK2 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.